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CLINICAL SARCOMA RESEARCH

Open Access

REVIEW

Fifteen years of irinotecan therapy
for pediatric sarcoma: where to next?
Lars M. Wagner*

Abstract
Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This
review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of
administration, and amelioration of side effects. Also discussed are new pegylated and nanoliposomal formulations
of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination
with other conventional cytotoxic as well as targeted agents.
Keywords: Irinotecan, Sarcoma, Ewing sarcoma, Rhabdomyosarcoma
Background
Irinotecan is a camptothecin analogue that has taken on
growing importance in the treatment of pediatric sarcomas such as Ewing sarcoma and rhabdomyosarcoma.
Irinotecan is a prodrug that is spontaneously converted
by endogenous carboxylesterases to its active metabolite, SN-38. Like other camptothecins such as topotecan,
SN-38 mediates cytotoxicity by stabilizing the DNAtopoisomerase I complex created during replication. This
stabilization prevents religation of DNA, and so “poisons” the activity of the topoisomerase I enzyme.
Irinotecan was initially approved by the US Food and
Drug Administration for the treatment of colon cancer
in 1996. Three years later, Furman et al. reported the
first pediatric phase I clinical trial of irinotecan [1]. This
landmark study was based on the preclinical observation
of improved efficacy when using a protracted multi-day
schedule, as opposed to a single dose given every 3 weeks
[2]. Such protracted scheduling provides greater exposure of this S phase-specific drug, especially when given
for 5 consecutive days 2 weeks in a row (d × 5 × 2 schedule). The objective responses observed in three patients
with relapsed rhabdomyosarcoma were consistent with
the enhanced preclinical activity seen in pediatric sarcoma xenografts using this schedule, and this trial was
*Correspondence: lars.wagner@uky.edu
Division of Pediatric Hematology/Oncology, Kentucky Clinic Suite,
University of Kentucky, J‑457, Lexington, KY 40536, USA

followed by subsequent studies designed to: (1) explore
various schedules of administration, (2) reduce toxicity,
(3) improve convenience and maximize SN-38 exposures,
and (4) define the activity of irinotecan as a single agent
and in combination with other drugs. In this review, we
will identify key findings from these past studies, and
also discuss new formulations and potentially synergistic
therapeutic partners for irinotecan.

Schedules of irinotecan administration
Several schedules of irinotecan administration have
been studied in children, ranging from one large dose
every 3 weeks as used in adults [3, 4], to once weekly [5],
daily × 3 [6], daily × 5 [7], and the original d × 5 × 2
schedule first studied by Furman et al. [1, 8, 9]. All schedules have been tolerable, although notably the pattern of
toxicity is schedule-dependent. For example, when using
larger but infrequent dosages, the principal toxicity is
myelosuppression. In contrast, diarrhea and abdominal
pain are more prominent with the protracted lower-dose
schedule.
Only one pediatric study has directly compared the
efficacy of different schedules of irinotecan. In that trial,
89 evaluable patients with recurrent rhabdomyosarcoma were randomized to receive vincristine combined
with irinotecan given either on a d × 5 or a d × 5 × 2
schedule [10]. The overall incidence of grade 3–4 adverse
events was similar. As expected, patients on the shorter
schedule experienced more myelosuppression, while
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those on the longer schedule had more gastrointestinal
toxicity. Importantly, because there was no significant
difference in efficacy, and since the shorter schedule is
more convenient and less expensive, the d × 5 schedule
has emerged as the most popular schedule for newer
regimens.

Ameliorating toxicity
In most pediatric studies of irinotecan, myelosuppression is mild and growth factor is rarely required. Instead,
diarrhea and abdominal pain are the usual dose-limiting toxicities. Early-onset diarrhea may occur during or
immediately after irinotecan administration, and is usually manageable with atropine. More common and problematic is the late-onset diarrhea noted about 1 week
after starting therapy. While prompt administration of
loperamide may help with mild gastrointestinal toxicity,
some patients experience severe diarrhea and abdominal pain, and this morbidity can impact compliance even
when the tumor is responding to treatment [7, 8].
The mechanism of late-onset diarrhea is complex.
Local accumulation of the active metabolite SN-38 in
the gut results in direct cytotoxicity and secretory diarrhea [11]. SN-38 is usually inactivated through hepatic
glucuronidation and then excreted in the bile into the
intestine. However, reactivation of SN-38 can occur as a
result of glucuronidases which are produced by enteric
bacteria [reviewed in 12]. Therefore, one approach for
reducing irinotecan-associated diarrhea is to use antibiotics to eradicate the Gram negative aerobic bacteria that
produce these glucuronidases, thereby reducing the reactivation of local SN-38 in the gut. That strategy proved
efficacious in a phase I trial of orally administered irinotecan in which the daily use of the oral cephalosporin
cefixime reduced the incidence of grade 3–4 diarrhea
such that the maximum tolerated dose was 50 % higher
than what could be achieved without antibiotic support
[13]. A 50 % increase in the tolerable dose was also noted
in patients receiving intravenous irinotecan in a similar
trial [14]. This practice of using cephalosporins before,
during, and after the irinotecan course has now been universally employed in all pediatric trials of orally administered irinotecan, given that the poor bioavailability
requires higher drug doses to achieve acceptable SN-38
exposures. One common approach when using the d × 5
schedule of irinotecan is to administer cephalosporins
(either cefixime or cefpodoxime) starting 2 days before
chemotherapy and continuing until 3 days after finishing
chemotherapy, which makes for a 10-day course of antibiotics and avoids the continuous administration that may
lead to antibiotic resistance or C difficile infections. In
contrast to orally administered irinotecan, cephalosporin
prophylaxis is not routinely done when standard doses
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of irinotecan are given intravenously, as the incidence of
≥grade 3 diarrhea is under 10 % [7]. Instead, antibiotic
prophylaxis is usually only used in patients experiencing
significant toxicity during the previous course, as a way
to maintain dose intensity [15].
The detoxification of SN-38 through hepatic glucuronidaiton is mediated by UGT1A1. In adult studies, patients with the UGT1A1*28 polymorphism have
increased toxicity from irinotecan [16]. However, in
pediatric studies this genotype/phenotype relationship
has not been observed. For example, in the largest series
of 74 patients taken from 5 pediatric studies in patients
receiving protracted irinotecan, there was no increase in
either hematologic or gastrointestinal toxicity in patients
homozygous for UGT1A1*28 [17]. Based on this and
similar reports [18], prospective genotyping of pediatric
patients receiving protracted irinotecan is not routinely
performed.

Maximizing convenience: oral administration
The protracted administration schedule of intravenous
irinotecan is inconvenient for patients and costly to
administer, prompting interest in oral administration.
There is no commercially available tablet or capsule formulation of irinotecan, and so the intravenous preparation has been given orally. Because of the bitter taste,
it is usually masked in cran-grape juice to improve palatability [13]. The oral bioavailability is less than 20 %,
requiring higher dose of oral irinotecan are necessary to
achieve SN-38 exposures similar to intravenous administration. However, metabolism of orally administered irinotecan is more efficient, given that the intestinal tract
contains high levels of carboxylesterases, which may presystemically metabolize irinotecan to SN-38 and increase
the SN-38/irinotecan ratio by threefold or more [19].
Pediatric clinical trials have shown the dose of 60 mg/
m2/dose on a d × 5 × 2 schedule was tolerable and produced SN-38 exposures that were similar to those seen
with intravenous doses of 20 mg/m2, when accounting
for the wide intrapatient variability in irinotecan metabolism [13, 18]. However, the relationship between oral and
intravenous dosing is not exactly linear. For example, the
daily oral dose of 90 mg/m2 appears comparable to the
intravenous dose of 50 mg/m2 when using similar pharmacokinetic assays [20]. To date there have been over 200
pediatric patients treated on trials of oral irinotecan [13,
18, 20–22]. Although there have been no studies directly
comparing the efficacy of oral vs. intravenous administration, the roughly similar SN-38 exposures, response
rates, and toxicity profiles suggest they are fairly equivalent when using the dose conversions noted above.
The benefits of oral administration include greater
patient convenience and time away from the clinic, as
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well as up to five-fold reduction in cost [23]. The strategy is generally feasible, and because of the considerable
benefits could be considered in most situations. However,
there are occasional patients who have difficulty taking
the medication orally, no matter what methods are used
to mask the flavor. Also, for patients with ongoing nausea
or chronic gastrointestinal complaints, oral absorption
may be limited and make this strategy inappropriate.

Improving SN‑38 exposure
Efforts to increase SN-38 exposure are based on the
assumption of a dose–response relationship for irinotecan therapy for pediatric sarcoma, which is intuitive but
not yet proven clinically. Given gastrointestinal toxicity is
the usual limiting toxicity, one strategy for dose escalation
is to reduce irinotecan-associated diarrhea with cefixime as described above. McGreggor et al. have shown
in a phase I trial this approach allows for an increase in
intravenous irinotecan dosing from 20 to 30 mg/m2/day
on the d × 5 × 2 schedule [14], although the efficacy of
higher doses has not been formally assessed.
Another strategy to increase drug exposure is to reduce
efflux of irinotecan out of cells by using the small molecule gefitinib to inhibit the ABCG2 drug transporter.
Through this mechanism gefitinib can reverse irinotecan
resistance in vitro even in cell lines that lack amplification of the epidermal growth factor receptor [24], which
is the usual therapeutic target for this agent. ABCG2 is
expressed in the small intestine, and co-administration
of gefitinib can increase the bioavailability of oral irinotecan by four-fold [25]. Dose-finding studies of gefitinib in
combination with both intravenous and oral irinotecan
have been reported [22, 25], but there has not yet been
efficacy assessment in a phase II trial.
Activity of single‑agent irinotecan
Single-agent irinotecan has been studied in a variety
of pediatric trials. As predicted from mouse xenograft
models [2, 26], responses have consistently been seen
in patients with rhabdomyosarcoma and Ewing sarcoma. Response rates as high as 38 % for Ewing sarcoma/
primitive neuroectodermal tumor and 16 % for rhabdomyosarcoma have been reported [9]. However, activity
of single-agent irinotecan in larger multi-institutional
phase II studies has been disappointing. For example,
in a Children’s Oncology Group (COG) phase II trial
using intravenous administration on a d × 5 schedule,
response rates in relapsed patients were under 10 % for
both rhabdomyosarcoma and Ewing sarcoma [7]. These
results have led to the current practice of partnering
irinotecan with another agent, such as vincristine or
temozolomide, as described below. There is less experience using irinotecan for treatment of osteosarcoma or
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non-rhabdomyosarcoma soft tissue sarcoma, with only
rare responses noted [20, 27].

Identifying potential therapeutic partners
Preclinical experience shows camptothecins can synergize with microtubule inhibitors such as vincristine
[28]. This combination has been most thoroughly evaluated in rhabdomyosarcoma, a disease in which vincristine is an established active agent. In newly-diagnosed
patients with metastatic rhabdomyosarcoma, Pappo
et al. reported a response rate of 42 % with single-agent
irinotecan, which increased to 70 % when combined
with vincristine [15]. The vincristine + irinotecan (VI)
combination is tolerable, and a recent phase III trial for
newly-diagnosed intermediate-risk rhabdomyosarcoma
showed that incorporating cassettes of VI alternating
with vincristine, dactinomycin, and cyclophosphamide
(VAC) is as effective as using VAC alone, which had historically been the standard treatment for these patients
[29]. As expected, febrile neutropenia and thrombocytopenia were less in patients receiving the VI cassettes,
although there was more diarrhea. Moving forward, the
COG is planning to use the VAC + VI regimen because
it reduces the overall exposure to alkylating agents that
may cause secondary malignancies and infertility.
Irinotecan has also been paired with the methylating agent temozolomide, given that modest myelosuppression seen from irinotecan allows for combination
with drugs having more hematologic toxicity. Houghton
et al. demonstrated schedule-dependent synergy with
these two drugs against rhabdomyosarcoma xenografts
[30], with maximum activity seen when temozolomide
is given at least 1 h before irinotecan [31]. This is consistent with the proposed mechanism in which temozolomide-induced methylation of DNA causes localization
of topoisomerase I-DNA complexes that are more susceptible to the cytotoxic effects of irinotecan [32]. This
temozolomide + irinotecan (TI) combination has been
particularly active in Ewing sarcoma, with reported
response rates between 29 and 63 % [33–35]. The doselimiting toxicities of irinotecan (diarrhea) and temozolomide (myelosuppression) are non-overlapping, and
the combination is well-suited for oral administration.
Because of the tolerability of this regimen, investigators
have used TI as a backbone on which to add other drugs
such as vincristine [20, 36, 37], as well as biologic agents
discussed below.
A variety of other conventional chemotherapy agents
have been combined with irinotecan to treat pediatric sarcoma, including carboplatin [38], oxaliplatin and/
or gemcitabine [39–41], ifosfamide [42], and docetaxel
[43]. None have achieved the response rates reported
with VI or TI, and in some cases unexpected toxicities
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Table 1 Key phase II and III studies using irinotecan in pediatric sarcoma patients
Reference Lead author Phase Other agents given with
irinotecan

Population

Comments

[30]

Hawkins

III

Vincristine

Newly-diagnosed
intermediate-risk RMS

VI alternating with VAC is as efficacious as VAC
alone, and may reduce long-term toxicity

[15]

Pappo

II

Vincristine

Newly-diagnosed metastatic RMS Response rate to induction rose from 46–70 %
after addition of vincristine

[38]

Dharmajan

II

Carboplatin, radiation

Newly-diagnosed intermediate
or high-risk RMS

Local control rate of 89 %; reduced mucositis
compared to historical controls

[10]

Mascarenhas II

Vincristine

Relapsed RMS

[37]

Mixon

II

Temozolomide, vincristine

Relapsed RMS

Similar rates of response and grade 3–4 toxicity
between d × 5 vs d × 5 × 2 schedule

[33]

Kurucu

II

Temozolomide

Relapsed ES

Response rate 55 %

[34]

Wagner

II

Temozolomide

Relapsed ES

Response rate 29 %

[35]

Casey

II

Temozolomide

Relapsed ES

Response rate 63 %

[36]

Raciborska

II

Temozolomide, vincristine

Relapsed ES

Response rate 68 %

[43]

Yoon

II

Docetaxel

Relapsed ES

Response rate 33 %

[42]

Crews

II

Ifosfamide

Newly-diagnosed high-risk
osteosarcoma

Ifosfamide reduced SN-38 exposures

One complete response in 4 patients

RMS rhabdomyosarcoma, ES Ewing sarcoma

or pharmacokinetic interactions were seen. For example,
although intermittent dosing of oxaliplatin and irinotecan was well tolerated in adults with colon cancer, severe
pancreatic inflammation was seen when oxaliplatin was
used together with protracted irinotecan in children [39].
Further, in a combination trial of ifosfamide and irinotecan for osteosarcoma patients, markedly reduced concentrations of SN-38 were noted, suggesting a major drug
interaction that could compromise efficacy [42]. These
findings demonstrate the importance of performing
dose-finding and pharmacokinetic studies for novel combinations. A summary of published combination phase II
and III studies of irinotecan-based regimens for pediatric
sarcoma is provided in Table 1.

Future combinations to be explored
One focus in sarcoma therapeutics has been the addition of targeted agents onto conventional chemotherapy
backbones. This strategy is particularly attractive if the
targeted agent has either single-agent activity, or if it
potentiates the cytotoxicity of standard chemotherapy
drugs. An example is the addition of mTOR inhibitors
such as temsirolimus to the TI regimen [21]. Responses
in rhabdomyosarcoma patients to single-agent temsirolimus have been limited [44], but its combination with
cyclophosphamide and vinorelbine showed promising activity in a recent COG trial [45]. Results from this
study provided the rationale for the next upcoming COG
phase III trial for intermediate-risk rhabdomyosarcoma,
which will study the VAC/VI backbone with or without
temsirolimus.

Another example is the combination of irinotecanbased regimens with a monoclonal antibody against the
insulin growth factor receptor type I receptor (IGF-1R).
Although the single-agent response rates to IGF-1R antibodies in phase II trials have been generally disappointing [reviewed in 46], there have been occasional patients
with impressive and durable responses in patients with
Ewing sarcoma and rhabdomyosarcoma [47, 48]. The
COG has recently completed a phase II trial of the IGF1R antibody cixutumumab together with multi-agent
conventional chemotherapy for patients with newly-diagnosed metastatic rhabdomyosarcoma (ClinicalTrials.gov
identifier NCT01055314). Interestingly, in the comparator arm of the study temozolomide was added on to the
same chemotherapy backbone, which included irinotecan. Final results of this study are not yet available.
A third example is the use of inhibitors against the
DNA repair protein poly(ADP-ribose) polymerase
(PARP). This class of drugs was identified through a functional genomics approach and found to have marked
preclinical in vitro and in vivo activity against Ewing
sarcoma [49]. Although efficacy as monotherapy may be
limited [50], the combination of a PARP inhibitor with
temozolomide is now being explored in multiple trials,
due to the potentiated effects of PARP inhibition following temozolomide-mediated DNA damage [51]. Stewart
et al. have recently reported that further preclinical benefit may be seen by combining PARP inhibitors with both
temozolomide and irinotecan [52].
Other molecular approaches include the targeting of
Wee1, which helps regulate the response to DNA damage
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by inhibiting CDK1. Wee1 can be targeted with the small
molecule MK-1775, which showed in vitro activity
against a variety of sarcoma cell lines [53]. Combination
with oral irinotecan is now being explored in a COG
Phase I trial (ClinicalTrials.gov identifier NCT02095132),
based on preclinical synergy with of this combination in
neuroblastoma models [54].
It is important to note that not all irinotecan combinations may show benefit for sarcoma, even if used commonly for other tumor types. Although widely employed
to treat high-grade glioma, the combination of irinotecan
and the anti-VEGF antibody bevacizumab has shown no
evidence to date of compelling activity in sarcoma in the
limited studies to date [55, 56].

New formulations of irinotecan and SN‑38
The process of pegylation joins a drug with a multimeric polyethylene glycol using a glycine linker in order to
prolong exposure to the agent. This approach has been
applied in an effort to prolong the exposure to irinotecan and/or SN-38. These approaches are attractive in that
preclinical studies have demonstrated responses even in
irinotecan-resistant xenografts [57], and the schedule of
administration is less frequent and therefore more convenient for patients. In a dose-finding study of pegylated
SN-38 (EZN-2208), a maximum tolerated dose of 24 mg/
m2 once every 3 weeks was identified, which was higher
than the adult MTD of 16.5 mg/m2 [58]. Some gastrointestinal toxicity was seen at lower doses, with myelosuppression being dose-limiting at the higher doses.
Unfortunately, no responses were seen in the 12 sarcoma
patients treated on this phase I trial.
The pegylated irinotecan compound etirinotecan
(NKTR-102) has shown promising activity in phase II
studies of breast and ovarian cancer using a once every
3 weeks schedule [59, 60], and is moving forward in phase
III trials. With this formulation, dehydration and diarrhea
were the most common grade 3–4 toxicities, occurring in
just over 20 % of patients. No trials have yet been reported
which partner either of these drugs with other agents, and
the long-term future of these agents likely awaits a review
of their benefits in larger upcoming trials.
Liposomal preparations of irinotecan have also been
developed, and may preferentially accumulate in tumor
cells through enhanced permeability and retention [61].
Nanoliposomal irinotecan (MM-398) also minimizes
exposure of drug in the serum and so stabilizes the active
lactone form of irinotecan versus the inactive carboxylate
form [62]. This drug has superior activity over comparably dosed conventional irinotecan in mouse models of
Ewing sarcoma [63], and is currently being evaluated in
a pediatric clinical trial together with cyclophosphamide
(ClinicalTrials.gov identifier NCT02013336).
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Conclusions
The role of irinotecan in combination with other agents is
becoming more established for the treatment of rhabdomyosarcoma, as well as for relapsed Ewing sarcoma. The
d × 5 schedule may be as effective as more protracted
administration, and is being used for many current and
planned irinotecan trials. Oral administration is feasible for the majority of patients, may have similar activity and toxicity, and offers reduced cost and time away
from the clinic. For these reasons, oral administration
using a 5-day schedule is now commonly employed in
the relapse setting at our institution, as well as in several
ongoing clinical trials. Prophylaxis with cephalosporins is
an important way to reduce severe irinotecan-associated
diarrhea, and is necessary for all patients receiving oral
administration of irinotecan. At present there is not a
reliable way to identify patients at greatest risk of toxicity, and antibiotic prophylaxis is not routinely necessary
for patients receiving intravenous irinotecan at standard
doses. The single-agent activity of irinotecan is limited,
although its toxicity profile allows for ready combination
with a variety of other chemotherapy drugs, especially
vincristine and temozolomide. Particularly exciting is the
potential for combining irinotecan-based backbones with
newer targeted therapies, and the opportunities for testing of the new longer-acting preparations either alone or
in combination with other drugs.
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